Digital Twins & In Silico Trials

Dassault Systèmes SIMULIA (Living Heart Project)

by Dassault Systèmes SE

4.4
0

Physics-based virtual human simulation enabling in silico clinical trials for cardiovascular devices and drugs

Category

Digital Twins & In Silico Trials

Founded

1981

Headquarters

Vélizy-Villacoublay, France

Overview

Dassault Systèmes SIMULIA develops computational simulation software for physics-based modeling of biological systems, with its Living Heart Project representing the most advanced publicly shared cardiac digital twin platform. The Living Heart Human Model is an anatomically accurate, biophysically detailed finite element model of the human heart that simulates electrical conduction, mechanical contraction, and fluid dynamics simultaneously. Built on the Abaqus FEA solver and 3DEXPERIENCE platform, it enables medical device companies to perform virtual clinical testing of cardiac devices — pacemakers, stents, valves, and electrophysiology catheters — before first-in-human studies. Medical device manufacturers, pharmaceutical companies modeling cardiac drug effects, and regulatory agencies including FDA use SIMULIA's in silico models to assess device safety, optimize designs, and study patient-specific cardiovascular mechanics. The FDA has accepted computational modeling submissions for cardiac device approval based on SIMULIA software, establishing a regulatory precedent for in silico clinical trials. Beyond cardiology, SIMULIA's simulation capabilities extend to bone mechanics, respiratory dynamics, and drug delivery device modeling. SIMULIA's competitive advantage is its multi-physics simulation fidelity: unlike statistical digital twin approaches, its finite element models solve coupled electrical-mechanical-fluidic equations grounded in first-principles physics, producing predictions that generalize to novel device geometries and patient anatomies not represented in training data. The Living Heart Project's open consortium model — bringing together medical device companies, pharmaceutical companies, academics, and regulators on a shared platform — has accelerated validation and regulatory acceptance of cardiac in silico methods in ways that proprietary platforms cannot achieve.

Key Features

Organ System Models

Detailed models of cardiovascular, hepatic, renal, and neural organ systems for PBPK simulation.

Trial Design Optimization

AI-optimized trial design including dosing schedules, endpoints, and patient stratification.

Regulatory Evidence Generation

Generate computational evidence packages aligned with FDA guidance for regulatory submissions.

Real-World Data Integration

Calibrate and validate models using real-world clinical data from healthcare systems.

Virtual Patient Modeling

Create digital patient models simulating drug responses across diverse population demographics.

Pros & Cons

Pros

  • +Predictive toxicology models identify safety liabilities before first-in-human dosing
  • +Integration with real-world clinical data improves model calibration and prediction accuracy
  • +Virtual patient models simulate drug responses across diverse population demographics
  • +In silico clinical trials reduce time and cost of traditional Phase I-III studies by 30-50%
  • +Multi-scale modeling connects molecular interactions to organ-level physiological responses
  • +Regulatory acceptance growing with FDA guidance on computational modeling for device and drug evaluation

Cons

  • Computational models cannot fully capture the complexity of human biological variability
  • Requires extensive clinical data for initial model calibration and ongoing validation
  • Adoption requires significant cultural change in organizations accustomed to traditional trial designs
  • Model validation against real clinical data is essential but time-consuming and expensive
  • Regulatory acceptance of in silico evidence varies across jurisdictions and therapeutic areas

Use Cases

Research Workflow Optimization

AI-powered optimization of research workflows to accelerate discovery timelines and improve reproducibility.

Data Analysis & Insights

Machine learning analysis of complex biological datasets to extract actionable insights and identify patterns.

Collaboration & Knowledge Management

Platform-enabled collaboration across distributed research teams with integrated data sharing and knowledge capture.

Last updated: February 19, 2026